1. Piram M, Mahr A (2013): Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. Curr Opin Rheumatol 25: 171-178.
2.
Heineke MH, Ballering AV, Jamin A, et al. (2017): New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev 16: 1246-1253.
3.
Demir S, Kaplan O, Celebier M, et al. (2020): Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. Semin Arthritis Rheum 50: 1238-1244.
4.
Ozen S, Pistorio A, Iusan SM, et al. (2010): EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69: 798-806.
5.
Mizerska-Wasiak M, Kusztal M. Zapalenie naczyń związane z IgA. In: Zapalenia naczyń w praktyce klinicznej interdyscyplinarnie. Kołacz A, Kossarzecka E (Eds.). PZWL Wydawnictwo Lekarskie, Warszawa 2022; 416-418.
6.
Sestan M, Jelusic M (2023): Diagnostic and management strategies of IgA vasculitis nephritis/Henoch-Schönlein purpura nephritis in pediatric patients: Current perspectives. Pediatric Health Med Ther 14: 89-98.
7.
Komatsu H, Fujimoto S, Yoshikawa N, et al. (2016): Clinical manifestations of Henoch- Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 20: 552-560.
8.
Delbet JD, Parmentier C, Rea CH, et al. (2021): Management of IgA vasculitis with nephritis. Pediatric Drugs 23: 425-435.
9.
Pohl M (2015): Henoch-Schönlein purpura nephritis. Pediatr Nephrol 30: 245-252.
10.
Dyga K, Szczepańska M (2020): IgA vasculitis with nephritis in children. Adv Clin Exp Med 29: 513-519.
11.
Pillebout E, Jamin A, Ayari H, et al. (2017): Biomarkers of IgA vasculitis nephritis in children. PLoS One 12: e0188718.
12.
Shi D, Chan H, Yang X, et al. (2019): Risk factors associated with IgA vasculitis with nephritis (Henoch-Schonlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. PLoS One 14: e0223218.
13.
Mizerska-Wasiak M, Turczyn A, Cichoń-Kawa K, et al. (2021): IgA vasculitis nephritis clinical course and kidney biopsy – national study in children. Pediatric Rheumatology 19: 150.
14.
Edstrom-Halling S, Soderberg MP, Berg UB (2010): Predictors of outcome in Henoch-Schonlein nephritis. Pediatr Nephrol 25: 1101-1108.
15.
Kawasaki Y, Suzuki J, Sakai N, et al. (2003): Clinical and pathological features of children with Henoch-Schonlein nephritis: risk factors associated with poor prognosis. Clin Nephrol 60: L153-160.
16.
Mir S, Yavascan O, Mutlubas F, et al. (2007): Clinical outcome in children with Henoch-Schonlein nephritis. Pediatr Nephrol 22: 64-70.
17.
Chan H, Tang YL, Lv XH, et al. (2016): Risk factors associated with renal involvement in childhood Henoch-Schonlein purpura: a meta-analysis. PLoS One 11: e0167346.
18.
Jelusic M, Sestan M, Cimaz R, et al. (2019): Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? Pediatr Rheumatol 17: 10.
19.
Trimarchi H, Barratt J, Cattran DC, et al. (2017): IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Conference Participants. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91: 1014-1021.
20.
Jelusic M, Sestan M, Giani T, Cimaz R (2022): New insights and challenges associated with IgA vasculitis and IgA vasculitis with nephritis – is it time to change the paradigm of the most common systemic vasculitis in childchood? Front Pediatr 10: 853724.
21.
Pan YX, Ye Q, Shao WX, et al. (2014): Relationship between immune parameters and organ involvement in children with Henoch-Schönlein purpura. PLoS One 9: e115261.
22.
Chen XQ, Tu L, Tang Q, et al. (2022): An emerging role for neutrophil extracellular traps in IgA vasculitis: A mini-review. Front Immunol 13: 912929.
23.
Suzuki H, Yasutake J, Makita Y, et al. (2018): IgA nephropathy and Iga vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 93: 700-705.
24.
Nusken E, Weber LT (2022): IgA vasculitis nephritis. Curr Opin Pediatr 34: 209-216.
25.
Peruzzi L, Coppo R (2021): IgA vasculitis nephritis in children and adults: one or different entities? Pediatr Nephrol 36: 2615-2625.
26.
Suzuki H, Kiryluk K, Novak J (2011): The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1803.
27.
Chua JS, Zandbergen M, Wolterbeek R, et al. (2019): Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. Mod Pathol 32: 1147-1157.
28.
Imai T, Nishiyama K, Ueki K, et al. (2020): Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch-Schonlein purupura nephritis. Clin Transl Immunology 9: e1212.
29.
Hastings MC, Rizk DV, Kiryluk K, et al. (2022): IgA vasculitis with nephritis: update of pathogenesis with clinical implications. Pediatr Nephrol 37: 719-733.
30.
Morton HC, Brandtzaeg P (2001): CD89: the human myeloid IgA Fc receptor. Arch Immunol Ther Exp 49: 217-229.
31.
Haddad E, Moura IC, Arcos-Fajardo M, et al. (2003): Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 14: 327-337.
32.
Wang J, Ying Q, Zhong S, et al. (2018): Elevated urinary monocyte chemoattractant protein-1 levels in children with Henoch-Schonlein purpura nephritis. Pediatr Neonatol 59: 238-243.
33.
Davin JC, Coppo R (2014); Henoch-Schonlein purpura nephritis in children. Nat Rev Nephrol 10: 563.
34.
He X, Yu C, Zhao P, et al. (2013): The genetics of Henoch-Schonlein purpura: a systematic review and meta-analysis. Rheumatol Int 33: 1387-1395.
35.
Oni L, Sampath S (2019): Childhood IgA vasculitis (Henoch-Schonlein purpura) – advances and knowledge gaps. Fron Pediatr 7: 257.
36.
Berthelot L, Jamin A, Viglietti D, et al. (2018): Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrol Dial Transplant 33: 1579-1590.
37.
Larson H, Chan E, Sudarsanam S, Johnson DE (2013): Biomarkers. Methods Mol Biol 930: 253-273.
38.
Mizerska-Wasiak M, Gajewski Ł, Cichoń-Kawa K, et al. (2018): Serum GDIgA1 levels in children with IgA nephropathy and Henoch-Schönlein nephritis. Cent Eur J Immunol 43: 162-167.
39.
Zhang X, Xie X, Shi S, et al. (2020): Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. Nephrol Dial Transplant 35: 2117-2123.
40.
Suzuki H, Moldoveanu Z, Julian BA, et al. (2019): Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep 4: 1717-1724.
41.
An JK, Xia D (2018): Diagnostic performance of urinary proteins as biomarkers in evaluating Henoch Schonlein purpura nephritis. Clin Exp Med 11: 12354-12360.
42.
Mayer-Hain S, Gebhardt K, Neufeld M, et al. (2022): Systemic activation of neutrophils by immune complexes is critical to IgA vasculitis. J Immunol 209: 1048-1058.
43.
Coppo R, Basolo B, Martina G, et al. (1982): Circulating Immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity. Clin Nephrol 18: 230-239.
44.
Davin JC, Ten Berge IJ, Weening JJ (2001): What the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int 59: 823-834.
45.
Monteiro RC, Kubagawa H, Cooper MD (1990): Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med 171: 597-613.
46.
Moresco RN, Speeckaert MM, Zmonarski SC, et al. (2016): Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and Henoch-Schönlein purpura nephritis. BBA Clin 5: 79-84.
47.
Delanghe SE, Speeckaert MM, Segers H, et al. (2013): Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schönlein purpura nephritis. Clin Biochem 46: 591-597.
48.
Williams CEC, Toner A, Wright RD, Oni L (2021): A systematic review of urine biomarkers in children with IgA vasculitis nephritis. Pediatr Nephrol 36: 3033-3044.
49.
Zhang R, Sung SHP, Feng G, et al. (2018): Aggregation-induced emission probe for specific turn-on quantification of soluble transferrin receptor: An important disease marker for iron deficiency anemia and kidney diseases. Anal Chem 90: 1154-1160.
50.
Zhang Q, Yan L, Chen M, et al. (2019): IgA1 isolated from Henoch-Schönlein purpura children promotes proliferation of human mesangial cells in vitro. Cell Biol Int 43: 760-769.
51.
Yuan L, Wang Q, Zhang S, Zhang L (2018): Correlation between serum inflammatory factors TNF-, IL-8, IL-10 and Henoch-Schonlein purpura with renal function impairment. Exp Ther Med 15: 3924-3928.
52.
Lin CY, Yang YH, Lee CC, et al. (2006): Thrombopoietin and interleukin-6 levels in Henoch-Schonlein purpura. J Microbiol Immunol 39: 476-482.
53.
Kimura S, Takeuchi S, Soma Y, Kawakami T (2013): Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with Henoch-Schönlein purpura. Clin Exp Dermatol 38: 730-736.
54.
Marro J, Chetwynd AJ, Wright RD, et al. (2022): Urinary protein array analysis to identify key inflammatory markers in children with IgA vasculitis nephritis. Children 9: 622.
55.
Dyga K, Machura E, Swietochowska E, Szczepańska M (2020): Analysis of the association between kidney injury biomarkers concentration and nephritis in immunoglobulin A vasculitis: A pediatric cohort study. Int J Rheum Dis 23: 1184-1193.
56.
Mao YN, Liu WEI, Li YG, et al. (2012): Urinary angiotensinogen levels in relation to renal involvement of Henoch-Schonlein purpura in children. Nephrology 17: 53-57.
57.
Yi-fei M, Yu-feng L, Gui-mei G, et al. (2020): Changes of new urinary biomarkers in children with Henoch-Schonlein purpura nephritis. J Shanghai Jiaotong Univ Med Sci 40: 841.
58.
Shuiai Z, Huijun S, Weizhong G, et al. (2017): Evaluation of TGF-b1 and MCP-1 expression and tubulointerstitial fibrosis in children with Henoch-Schonlein purpura nephritis and IgA nephropathy: A clinical correlation. Clinics 72: 95-102.
59.
Fuentes Y, Hernandes AM, Garci-Roca P, et al. (2014): Urinary MCP-1/creatinine in Henoch-Schonlein purpura and its relationship with nephritis. Pediatr Nephrol 29: 1047-1052.
60.
Mizerska-Wasiak M, Płatos E, Cichoń-Kawa K, et al. (2022): The usefulness of vanin-1 and periostin as markers of an active autoimmune process or renal fibrosis in children with IgA nephropathy and IgA vasculitis with nephritis – a pilot study. J Clin Med 11: 1265.
61.
Demir S, Kaplan O, Celebier M, et al. (2020): Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. Semin Arthritis Rheum 50: 1238-1244.
62.
Sun L, Xie B, Zhang Q, et al. (2017): Biomarkers identification by a combined clinical and metabonomics analysis in Henoch-Schonlein purpura nephritis children. Oncotarget 8: 114239-114250.
63.
Coppo R, Fonsato V, Balegno S, et al. (2010): Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int 77: 417-427.